K

Kardigan

HealthUnited States

Kardigan is a cardiovascular drug startup focused on developing innovative treatments for heart conditions. The company has raised significant funding through both private venture capital and an initial public offering, highlighting its rapid growth and the increasing interest in biotech investments. Its lead drug, danicamtiv, is in late-stage testing for dilated cardiomyopathy, a condition currently lacking approved treatments.

$400M · IPOVisit website ↗

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
Featured in Datapile’s Q2 2026 USA Funding Report
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. $400MIPO2026-06-18
    Source: news.google.com ↗

More Health companies

Recently funded startups in the same category.

Related on Datapile